IOLCP receives EDQM CEP for Sitagliptin Phosphate Monohydrate
IOL Chemicals and Pharmaceuticals Limited received a Certificate of Suitability (CEP) from EDQM for its API product "Sitagliptin Phosphate Monohydrate" on 27th October 2025, enabling market access.
The EDQM CEP approval is a significant regulatory milestone that enables market access for a key pharmaceutical ingredient in the European market, which can lead to increased sales and business opportunities for the company.
The receipt of the EDQM CEP certificate is a positive development as it allows IOLCP to market its 'Sitagliptin Phosphate Monohydrate' API in Europe, potentially expanding its market reach and revenue streams.
IOL Chemicals and Pharmaceuticals Limited announced that the European Directorate for the Quality of Medicines & Health Care (EDQM) has issued a Certificate of Suitability (CEP) for the Company's API product, "Sitagliptin Phosphate Monohydrate". This certificate was issued on 27th October 2025. Sitagliptin Phosphate Monohydrate is an oral antidiabetic medication used to control high blood sugar levels.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.